MINT-HYDROXYCHLOROQUINE TABLET

Country: Canada

Language: English

Source: Health Canada

Active ingredient:

HYDROXYCHLOROQUINE SULFATE

Available from:

MINT PHARMACEUTICALS INC

ATC code:

P01BA02

INN (International Name):

HYDROXYCHLOROQUINE

Dosage:

200MG

Pharmaceutical form:

TABLET

Composition:

HYDROXYCHLOROQUINE SULFATE 200MG

Administration route:

ORAL

Units in package:

100/500

Prescription type:

Prescription

Therapeutic area:

ANTIMALARIALS

Product summary:

Active ingredient group (AIG) number: 0107403001; AHFS:

Authorization status:

APPROVED

Authorization date:

2014-05-26

Summary of Product characteristics

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MINT-HYDROXYCHLOROQUINE
Hydroxychloroquine Sulfate Tablets
Tablets, 200 mg, Oral
USP
Anti-Inflammatory – Antimalarial – Aminoquinolines
Mint Pharmaceuticals Inc.
6575 Davand Drive Mississauga,
Ontario
L5T 2M3
Date of Initial Authorization:
MAY 22, 2014
Date of Revision:
MAY 5, 2023
Submission Control Number: 273056
_MINT-HYDROXYCHLOROQUINE (hydroxychloroquine sulfate tablets _
_Page 2 of 43 _
_ _
RECENT MAJOR LABEL CHANGES
2 Contraindications
05/2021
4 Dosage and Administration, Pregnant
Women
11/2021
7 Warnings and Precautions, Hematologic
11/2021
7 Warnings and Precautions, Musculoskeletal
11/2021
7 Warnings and Precautions, Psychiatric
11/2021
7 Warnings and Precautions, Skin
01/2022
7 Warnings and Precautions, 7.1.1 Pregnant
Women
11/2021
7 Warnings and Precautions, 7.1.4 Geriatrics
11/2021
7 Warning and Precautions, Cardiovascular
05/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
CONTRAINDICATIONS
.................................................................................................
5
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1
Dosing Considerations:
......